[Steroid hormone receptors in breast cancer]

The significance of hormone receptor (estrogen(ER)- and progesterone receptor (PgR) assay was described with special reference to the treatment of advanced and early breast cancer. Fifty to sixty percent of ER-positive breast cancer responds to endocrine treatment, while only about 10% of ER-negative cancer do. Advanced breast cancer patients with ER-positive tumors survive longer than those with ER-negative tumors, mainly because of better response to therapy. The clinical benefit of assaying the hormone receptors in primary breast cancer was discussed, particularly concerning with the relapse-free and overall survivals of the patients after primary operation. The findings suggest the possibility of selecting operable breast cancer patients for the most appropriate adjuvant using ER and PgR.